Company Description
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States.
The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders.
The company has a collaboration with the Department of Neurology’s Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating epilepsy therapies.
The company is based in Eden Prairie, Minnesota.
| Country | United States |
| Founded | 2009 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 18 |
| CEO | David Rosa |
Contact Details
Address: 7599 Anagram Drive Eden Prairie, Minnesota 55344 United States | |
| Phone | 952 426 1383 |
| Website | nmtc1.com |
Stock Details
| Ticker Symbol | NMTC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001500198 |
| CUSIP Number | 64130M308 |
| ISIN Number | US64130M3088 |
| Employer ID | 27-0863354 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| David A. Rosa M.D. | President, Chief Executive Officer and Director |
| Ronald W. McClurg | Chief Financial Officer |
| Christopher R. Volker CFA | Chief Operating Officer |
| Mark Christianson | Co-Founder, Business Development Director and Medical Sales Liaison |
| Steven Mertens | Chief Technology Officer |
| Emily Johns | Chief Administrative Officer and General Counsel |
| Hijaz Haris | Vice President of Marketing |
| Dr. Parag G. Patil M.D., Ph.D. | Chief Medical Advisor |
| David J. Wambeke | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2026 | SCHEDULE 13G | Filing |
| Apr 14, 2026 | 8-K | Current Report |
| Apr 3, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 144 | Filing |
| Mar 9, 2026 | ARS | Filing |
| Mar 9, 2026 | DEF 14A | Other definitive proxy statements |
| Feb 27, 2026 | PRE 14A | Other preliminary proxy statements |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 17, 2026 | 10-Q | Quarterly Report |